Pacific Biosciences of California (NASDAQ: PACB) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its rivals? We will compare Pacific Biosciences of California to related companies based on the strength of its analyst recommendations, institutional ownership, risk, dividends, earnings, valuation and profitability.
This table compares Pacific Biosciences of California and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pacific Biosciences of California||-89.67%||-93.31%||-57.10%|
|Pacific Biosciences of California Competitors||-327.99%||-35.84%||-12.54%|
This is a breakdown of recent ratings for Pacific Biosciences of California and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pacific Biosciences of California||0||2||1||0||2.33|
|Pacific Biosciences of California Competitors||257||1819||3262||105||2.59|
Pacific Biosciences of California currently has a consensus price target of $8.93, suggesting a potential upside of 97.64%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 5.48%. Given Pacific Biosciences of California’s higher possible upside, equities research analysts plainly believe Pacific Biosciences of California is more favorable than its rivals.
Earnings and Valuation
This table compares Pacific Biosciences of California and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Pacific Biosciences of California||$95.83 million||-$75.40 million||-4.91|
|Pacific Biosciences of California Competitors||$2.02 billion||$430.74 million||-66.92|
Pacific Biosciences of California’s rivals have higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
68.3% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 17.8% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
Pacific Biosciences of California has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California’s rivals have a beta of 0.89, meaning that their average stock price is 11% less volatile than the S&P 500.
Pacific Biosciences of California rivals beat Pacific Biosciences of California on 8 of the 12 factors compared.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.
Receive News & Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related companies with MarketBeat.com's FREE daily email newsletter.